알레르기 진단 및 치료 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 알레르겐 유형별, 검사 유형별, 지역별, 부문별 예측(2026-2033년)

Allergy Diagnostics And Therapeutics Market Summary

The global allergy diagnostics and therapeutics market size was estimated at USD 37.10 billion in 2025 and is expected to reach USD 78.00 billion by 2033, projected to grow at a CAGR of 9.95% from 2026 to 2033. Some of the major factors driving the market are the rising prevalence of allergies, advancements in technology, the launch of new products, and the high adoption of immunotherapy drugs.

According to the FDA, the most common food allergies in the U.S. include milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, soybeans, and sesame. The CDC reported that 10% of patients in the U.S. claim to be allergic to penicillin; less than 1% are truly allergic. Changing lifestyle and growing pollution are some of the key factors contributing to the increasing incidence of allergic conditions. The introduction of therapeutically advanced drugs, namely immunotherapy, which solves unmet patient needs, is expected to boost market growth over the forecast period. For instance, in February 2024, the U.S. Food and Drug Administration approved Xolair (omalizumab) injection for immunoglobulin E-mediated food allergy in certain adults and children 1 year or older for the reduction of allergic reactions (Type I), including reducing the risk of anaphylaxis, that may occur with accidental exposure due to more than one food. In addition, Xolair is intended for repeated use to reduce the risk of allergic reactions and is not approved for the immediate emergency treatment of allergic reactions, including anaphylaxis.

The rising prevalence of allergies is one of the important reasons driving the growth of the allergy therapeutics market over the predicted period. High risk factors for chronic respiratory disorders include increased exposure to outdoor and indoor air pollution, as well as occupational exposure. Allergies are far more common in cities than in rural areas, owing to increased exposure to environmental contaminants as a result of industrial activity and urbanization. According to statistics published by the WHO in January 2024, around 1 in 4 children and 1 in 3 adults have a seasonal allergy in the U.S. Nearly 6% of children and adults in the U.S. suffer from a food allergy, with the rate being highest among black, Asian, and Hispanic individuals.

Increasing demand for IVD testing is likely to drive the market over the forecast period. In vitro blood tests are used to diagnose food, inhalation, skin, and medication allergies. These tests have several advantages, including the fact that they are minimally invasive, cost-effective, and user-friendly, which is expected to provide profitable growth prospects in this market. Furthermore, the development of low-cost and effective in vitro diagnostic tests for allergy detection, increased lab automation, and an increase in reagent rental agreements are all projected to contribute to market expansion in the future years.

In addition, rising funding for the development of IVD allergy tests is driving strong market growth. For instance, in October 2024, Allergios received a HealthHolland grant to strengthen a public-private partnership with Wageningen University & Research focused on verifying the GranulEye test, a cutting-edge food allergy diagnosis tool. The study, conducted by Dr. Janneke Ruinemans-Koerts, used both clinical and analytical methods to validate GranulEye for peanut allergy, comparing its basophil-activation visualization method to existing basophil activation tests. Unlike skin-prick tests, IgE tests, or the difficult double-blind placebo-controlled food challenge, GranulEye aims to diagnose actual clinical allergy rather than mere sensitization reliably.

Global Allergy Diagnostics And Therapeutics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global allergy diagnostics and therapeutics market report based on type, allergen type, test type, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnostics
  • Instruments
  • Consumables
  • Services
• Therapeutics
  • Antihistamines
  • Decongestants
  • Corticosteroids
  • Mast Cell Stabilizers
  • Leukotriene Inhibitors
  • Nasal Anti-cholinergic
  • Immuno-modulators
  • Epinephrine
  • Immunotherapy
• Allergen Type Outlook (Revenue, USD Million, 2021 - 2033)
• Food
  • Dairy Products
  • Poultry Product
  • Tree Nuts
  • Peanuts
  • Shellfish
  • Wheat
  • Soy
  • Other Food Allergens
• Inhaled
• Drug
• Other allergen types
• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• In Vivo Tests
  • Skin Prick Test
  • Intradermal Test
  • Patch Test
• In Vitro Tests
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Type Method
    • 1.1.1.2. Allergen Type Segment
    • 1.1.1.3. Test Type Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Type Snapshot
• 2.3. Allergen Type Snapshot
• 2.4. Type Snapshot
• 2.5. Competitive Landscape Snapshot

Chapter 3. Allergy Diagnostics and Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Rising incidence of allergies
  • 3.4.2. Advancements in technology and the launch of new products
  • 3.4.3. High adoption of immunotherapy drugs
• 3.5. Market Restraint Analysis
  • 3.5.1. Low adoption and penetration in developing countries due to the high cost of technology
  • 3.5.2. Lack of allergen standardization
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Allergy Diagnostics and Therapeutics Market: Type Method Estimates & Trend Analysis

• 4.1. Allergy Diagnostics and Therapeutics Market: Test Method Movement Analysis
• 4.2. Diagnostics
  • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.2. Instruments
    • 4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.3. Consumables
    • 4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.4. Services
    • 4.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.3. Therapeutics
  • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.2. Antihistamines
    • 4.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.3. Decongestants
    • 4.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.4. Corticosteroids
    • 4.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.5. Mast Cell Stabilizers
    • 4.3.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.6. Leukotriene Inhibitors
    • 4.3.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.7. Nasal Anti-cholinergic
    • 4.3.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.8. Immuno-modulators
    • 4.3.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.9. Epinephrine
    • 4.3.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.10. Immunotherapy
    • 4.3.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Allergy Diagnostics and Therapeutics Market: Allergen Type Estimates & Trend Analysis

• 5.1. Allergy Diagnostics and Therapeutics Market: Mode Movement Analysis
• 5.2. Food
  • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.2.2. Dairy Products
    • 5.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.2.3. Poultry Product
    • 5.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.2.4. Tree Nuts
    • 5.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.2.5. Peanuts
    • 5.2.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.2.6. Shellfish
    • 5.2.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.2.7. Wheat
    • 5.2.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.2.8. Soy
    • 5.2.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.3. Other Food Allergens
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Inhaled
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Drug
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Other allergen types
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Allergy Diagnostics and Therapeutics Market: Test Type Estimates & Trend Analysis

• 6.1. Allergy Diagnostics and Therapeutics Market: Type Movement Analysis
• 6.2. In Vivo tests
  • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.2.2. Skin Prick Test
    • 6.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.2.3. Intradermal Test
    • 6.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.2.4. Patch Test
    • 6.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.3. In Vitro tests
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Allergy Diagnostics and Therapeutics Market: Regional Business Analysis

• 7.1. Regional Market Snapshot
• 7.2. North America
  • 7.2.1. North America Allergy Diagnostics and Therapeutics Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. Competitive Scenario
    • 7.2.2.3. Regulatory Framework
    • 7.2.2.4. Reimbursement Scenario
    • 7.2.2.5. U.S. Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Competitive Scenario
    • 7.2.3.3. Regulatory Framework
    • 7.2.3.4. Reimbursement Scenario
    • 7.2.3.5. Canada Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Key Country Dynamics
    • 7.2.4.2. Competitive Scenario
    • 7.2.4.3. Regulatory Framework
    • 7.2.4.4. Reimbursement Scenario
    • 7.2.4.5. Mexico Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. Reimbursement Scenario
    • 7.3.2.5. UK Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Reimbursement Scenario
    • 7.3.3.5. Germany Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.3.4. Spain
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Reimbursement Scenario
    • 7.3.4.5. Spain Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.3.5. France
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Competitive Scenario
    • 7.3.5.3. Regulatory Framework
    • 7.3.5.4. Reimbursement Scenario
    • 7.3.5.5. France Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.3.6. Italy
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Competitive Scenario
    • 7.3.6.3. Regulatory Framework
    • 7.3.6.4. Reimbursement Scenario
    • 7.3.6.5. Italy Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Competitive Scenario
    • 7.3.7.3. Regulatory Framework
    • 7.3.7.4. Reimbursement Scenario
    • 7.3.7.5. Denmark Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Competitive Scenario
    • 7.3.8.3. Regulatory Framework
    • 7.3.8.4. Reimbursement Scenario
    • 7.3.8.5. Sweden Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Competitive Scenario
    • 7.3.9.3. Regulatory Framework
    • 7.3.9.4. Reimbursement Scenario
    • 7.3.9.5. Norway Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia-Pacific Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Scenario
    • 7.4.2.5. Japan Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.4.3. China
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Scenario
    • 7.4.3.5. China Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Scenario
    • 7.4.4.5. India Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.4.5. South Korea
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Reimbursement Scenario
    • 7.4.5.5. South Korea Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.4.6. Thailand
    • 7.4.6.1. Thailand Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
    • 7.4.6.2. Key Country Dynamics
    • 7.4.6.3. Competitive Scenario
    • 7.4.6.4. Regulatory Framework
    • 7.4.6.5. Reimbursement Scenario
    • 7.4.6.6. Thailand Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.4.7. Australia
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Reimbursement Scenario
    • 7.4.7.5. Australia Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Scenario
    • 7.5.2.5. Brazil Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Scenario
    • 7.5.3.5. Argentina Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
• 7.6. MEA
  • 7.6.1. MEA Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Scenario
    • 7.6.2.5. South Africa Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Scenario
    • 7.6.3.5. Saudi Arabia Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.6.4. UAE
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Scenario
    • 7.6.4.5. UAE Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Scenario
    • 7.6.5.5. Kuwait Allergy Diagnostics and Therapeutics Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Heat Map Analysis
• 8.4. Company Profiles
  • 8.4.1. R-Biopharm AG
    • 8.4.1.1. Company Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. EUROIMMUN Medizinische Labordiagnostika AG
    • 8.4.2.1. Company Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. DASIT Group SPA
    • 8.4.3.1. Company Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. AESKU.GROUP GmbH
    • 8.4.4.1. Company Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. bioMerieux
    • 8.4.5.1. Company Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Danaher
    • 8.4.6.1. Company Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Thermo Fisher Scientific, Inc
    • 8.4.7.1. Company Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Stallergenes Greer
    • 8.4.8.1. Company Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Minaris Medical America, Inc.
    • 8.4.9.1. Company Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Siemens Healthcare GmbH
    • 8.4.10.1. Company Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives
  • 8.4.11. Omega Diagnostics Group PLC
    • 8.4.11.1. Company Overview
    • 8.4.11.2. Financial Performance
    • 8.4.11.3. Product Benchmarking
    • 8.4.11.4. Strategic Initiatives
  • 8.4.12. HYCOR Biomedical
    • 8.4.12.1. Company Overview
    • 8.4.12.2. Financial Performance
    • 8.4.12.3. Product Benchmarking
    • 8.4.12.4. Strategic Initiatives
  • 8.4.13. Lincoln Diagnostics, Inc.
    • 8.4.13.1. Company Overview
    • 8.4.13.2. Financial Performance
    • 8.4.13.3. Product Benchmarking
    • 8.4.13.4. Strategic Initiatives
  • 8.4.14. Alcon
    • 8.4.14.1. Company Overview
    • 8.4.14.2. Financial Performance
    • 8.4.14.3. Product Benchmarking
    • 8.4.14.4. Strategic Initiatives
  • 8.4.15. HOB Biotech Group Corp., Ltd.
    • 8.4.15.1. Company Overview
    • 8.4.15.2. Financial Performance
    • 8.4.15.3. Product Benchmarking
    • 8.4.15.4. Strategic Initiatives
  • 8.4.16. AbbVie Inc.
    • 8.4.16.1. Company Overview
    • 8.4.16.2. Financial Performance
    • 8.4.16.3. Product Benchmarking
    • 8.4.16.4. Strategic Initiatives
  • 8.4.17. Allergy Therapeutics
    • 8.4.17.1. Company Overview
    • 8.4.17.2. Financial Performance
    • 8.4.17.3. Product Benchmarking
    • 8.4.17.4. Strategic Initiatives
  • 8.4.18. Sanofi
    • 8.4.18.1. Company Overview
    • 8.4.18.2. Financial Performance
    • 8.4.18.3. Product Benchmarking
    • 8.4.18.4. Strategic Initiatives
  • 8.4.19. Pfizer Inc.
    • 8.4.19.1. Company Overview
    • 8.4.19.2. Financial Performance
    • 8.4.19.3. Product Benchmarking
    • 8.4.19.4. Strategic Initiatives
  • 8.4.20. Teva Pharmaceutical Industries Ltd.
    • 8.4.20.1. Company Overview
    • 8.4.20.2. Financial Performance
    • 8.4.20.3. Product Benchmarking
    • 8.4.20.4. Strategic Initiatives
  • 8.4.21. Sun Pharmaceutical Industries Ltd.
    • 8.4.21.1. Company Overview
    • 8.4.21.2. Financial Performance
    • 8.4.21.3. Product Benchmarking
    • 8.4.21.4. Strategic Initiatives
  • 8.4.22. GSK plc
    • 8.4.22.1. Company Overview
    • 8.4.22.2. Financial Performance
    • 8.4.22.3. Product Benchmarking
    • 8.4.22.4. Strategic Initiatives
  • 8.4.23. F. Hoffmann-La Roche Ltd.
    • 8.4.23.1. Company Overview
    • 8.4.23.2. Financial Performance
    • 8.4.23.3. Product Benchmarking
    • 8.4.23.4. Strategic Initiatives
  • 8.4.24. Merck & Co., Inc.
    • 8.4.24.1. Company Overview
    • 8.4.24.2. Financial Performance
    • 8.4.24.3. Product Benchmarking
    • 8.4.24.4. Strategic Initiatives
  • 8.4.25. Astellas Pharma Inc.
    • 8.4.25.1. Company Overview
    • 8.4.25.2. Financial Performance
    • 8.4.25.3. Product Benchmarking
    • 8.4.25.4. Strategic Initiatives
  • 8.4.26. Epigenomics AG
    • 8.4.26.1. Company Overview
    • 8.4.26.2. Financial Performance
    • 8.4.26.3. Product Benchmarking
    • 8.4.26.4. Strategic Initiatives